Innate Pharma (Nasdaq: IPHA) schedules Q1 2026 business update webcast
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
Innate Pharma S.A. filed a Form 6-K to share a press release announcing a conference call and webcast to discuss its business progress for the first quarter of 2026. The call will take place on Wednesday, May 13, 2026 at 1:30 p.m. CEST / 7:30 a.m. EDT.
Management participants will include the Chief Executive Officer, Chief Medical Officer, Chief Operating Officer, Head of Investor Relations, and Chief Financial Officer. The event will be accessible via webcast and telephone, with a replay available on the company’s website for 90 days.
The release also briefly describes Innate Pharma as a global, clinical-stage biotechnology company focused on cancer immunotherapies, highlighting key programs such as IPH4502, lacutamab and monalizumab, and noting collaborations with partners including AstraZeneca and Sanofi.
Positive
- None.
Negative
- None.
Key Figures
Conference call date: May 13, 2026
Conference call time CEST: 1:30 p.m. CEST
Conference call time EDT: 7:30 a.m. EDT
+1 more
4 metrics
Conference call date
May 13, 2026
Q1 2026 business update call schedule
Conference call time CEST
1:30 p.m. CEST
Scheduled time for Q1 2026 call
Conference call time EDT
7:30 a.m. EDT
Scheduled time for Q1 2026 call
Webcast replay duration
90 days
Replay availability on company website
Key Terms
clinical-stage biotechnology company, immunotherapies, antibody therapeutics, Universal Registration Document, +2 more
6 terms
clinical-stage biotechnology company financial
"Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients."
immunotherapies technical
"developing immunotherapies for cancer patients."
Immunotherapies are medical treatments that strengthen or guide the body's own immune system to recognize and fight disease cells, such as cancer or chronic infections. They matter to investors because they can produce long-lasting patient responses, command premium prices, and reshape standard care—similar to installing a smarter security system that prevents repeat break-ins—creating significant commercial upside but also clinical and regulatory risk.
antibody therapeutics technical
"developing innovative and differentiated next-generation antibody therapeutics."
Antibody therapeutics are medicines made from proteins the immune system uses, engineered to stick to specific molecules or cells to block disease or mark them for removal. They matter to investors because successful antibody drugs can command high prices and large markets, but their value hinges on clinical trial outcomes, manufacturing complexity, regulatory approval and patent protection—like custom-made keys that can open big rewards or be hard to replicate.
Universal Registration Document regulatory
"refer to the Risk Factors section of the Universal Registration Document filed with the French Financial Markets Authority"
A universal registration document is a single, comprehensive filing that collects a publicly traded company's key disclosures — such as business description, financial statements, risk factors, governance and legal information — into one place for regulators and investors. Think of it as a detailed owner’s manual and scorecard combined: it saves time when the company issues new shares or bonds and helps investors compare, check risks, and make informed decisions without hunting through many separate reports.
Annual Report on Form 20-F regulatory
"including the Company’s Annual Report on Form 20-F for the year ended December 31, 2025"
An annual report on Form 20-F is a standardized filing that foreign companies submit to the U.S. securities regulator to disclose their financial results, business operations, risks, and management’s discussion of performance. It matters to investors because it provides a complete, audited snapshot—like a company’s financial report card and shareholder letter combined—used to assess transparency, compare companies, and judge whether the stock’s price matches underlying business strengths and risks.
non-small cell lung cancer medical
"monalizumab, an anti-NKG2A antibody developed in collaboration with AstraZeneca in non-small cell lung cancer."
A broad category of lung tumors that grow from the cells lining the airways and make up the majority of lung cancer cases; it includes several subtypes that behave and respond to treatment differently, like different models of the same car family. It matters to investors because its large patient population and variety of treatment options — surgery, traditional chemo, targeted drugs and immunotherapies — create major markets where clinical trial results, drug approvals or changing treatment guidelines can quickly affect a company’s revenue and stock value.
FAQ
What did Innate Pharma (IPHA) announce in this Form 6-K?
Innate Pharma announced a conference call and webcast to discuss its Q1 2026 business update. The event will feature senior management and provide an overview of business progress and pipeline developments for the first quarter of 2026.
When is Innate Pharma’s Q1 2026 business update conference call?
The Q1 2026 business update call is scheduled for Wednesday, May 13, 2026 at 1:30 p.m. CEST / 7:30 a.m. EDT. Investors can join via webcast or telephone using registration links provided in the announcement.
How can investors access Innate Pharma’s Q1 2026 webcast?
Investors can access the live webcast through an online link listed in the announcement and on Innate Pharma’s investor website. A replay of the webcast will be available on the company’s site for 90 days after the event.
Who from Innate Pharma’s leadership will speak on the Q1 2026 call?
The call will include Innate Pharma’s Chief Executive Officer, Chief Medical Officer, Chief Operating Officer, Vice President of Investor Relations, Communication & Commercial Strategy, and Chief Financial Officer. Together they will review business progress for the first quarter of 2026.
What type of company is Innate Pharma (IPHA)?
Innate Pharma is a global, clinical-stage biotechnology company developing cancer immunotherapies. It focuses on next-generation antibody therapeutics and is advancing assets such as IPH4502, lacutamab and monalizumab in solid tumors and lymphomas.